BioSpace News Archive

Exelixis, Inc. (Nasdaq: EXEL) today announced that the CONTACT-01 study did not meet its primary endpoint of overall survival at the final analysis. CONTACT-01 is a phase 3 trial evaluating cabozantinib (CABOMETYX®).

Bristol Myers Squibb announced that its Board of Directors has declared a quarterly dividend of fifty-seven cents per share on the $.10 par value common stock of the company.

Labcorp (NYSE: LH), a leading global life sciences company, today announced that it has begun operations at a new, larger anatomic pathology and histology (APH) laboratory in Los Angeles, expanding the company’s global central laboratory capabilities.

Initial results from the TROPION-PanTumor01 phase 1 trial of datopotamab deruxtecan showed encouraging and durable efficacy in patients with heavily pretreated hormone receptor positive, HER2 low or HER2 negative unresectable or metastatic breast cancer.

Prometheus Biosciences, Inc. announced the pricing of an underwritten offering of 4,545,455 shares of its common stock at a price to the public of $110 per share.

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced the submission of its supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) for patisiran, an investigational RNAi therapeutic in development for the treatment of transthyretin-mediated (ATTR) amyloidosis with cardiomyopathy.

The board of directors of Medtronic plc on Thursday, December 8, 2022, approved the fiscal year 2023 third quarter cash dividend of $0.68 per ordinary share, representing an 8% increase over the prior year.